BUZZ-Ideaya Biosciences rises on data from mid-stage cancer study

Reuters07-08

** Shares of oncology-focused biotech firm Ideaya Biosciences rise 14.4% to $39.17

** Co announced positive results from a mid-stage study testing a higher dose of its experimental cancer drug in pre-treated patients with a type of bladder and lung cancer

** Co says the drug called IDE397 showed an overall response rate of 39%, the proportion of patients whose cancers disappeared or shrank

** Adds, 14 out of 18 patients observed tumor shrinkage

** Co says there were no drug related serious adverse events observed

** Says IDE397 expansion dose of 30 mg once-a-day achieved target drug coverage

** Including session moves, stock up 9.2% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment